$ASPI
ASP Isotopes Inc.

2023 Q3 Form 10-Q Financial Statement

#000147793223006112 Filed on August 14, 2023

View on sec.gov

Income Statement

Concept 2023 Q3 2023 Q2 2022 Q4
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue $0.00 $0.00
YoY Change
Gross Profit $0.00 $0.00
YoY Change
Gross Profit Margin
Selling, General & Admin $3.710M $4.095M $1.377M
YoY Change 207.04% 230.28%
% of Gross Profit
Research & Development $239.2K $252.9K $94.44K
YoY Change -67.91% -43.36%
% of Gross Profit
Depreciation & Amortization $802.00 $167.00
YoY Change
% of Gross Profit
Operating Expenses $3.947M $4.348M $1.472M
YoY Change 101.99% 157.83%
Operating Profit -$3.947M -$4.348M
YoY Change 101.99% 425.09%
Interest Expense $0.00 $1.100K $1.480K
YoY Change -100.0% -24.14%
% of Operating Profit
Other Income/Expense, Net -$276.0K $61.20K $166.2K
YoY Change 9416.31% 7656.4%
Pretax Income -$4.220M -$4.286M -$1.304M
YoY Change 115.72% 154.42%
Income Tax $0.00 $0.00
% Of Pretax Income
Net Earnings -$4.222M -$4.286M -$1.304M
YoY Change 115.85% 154.42%
Net Earnings / Revenue
Basic Earnings Per Share -$0.14 -$0.14
Diluted Earnings Per Share -$0.14 -$0.14 -$0.06
COMMON SHARES
Basic Shares Outstanding 37.39M shares 37.39M shares 34.36M shares
Diluted Shares Outstanding 31.15M

Balance Sheet

Concept 2023 Q3 2023 Q2 2022 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments $2.290M $3.626M $2.389M
YoY Change 430.62% 28.89%
Cash & Equivalents $2.287M $3.626M $2.389M
Short-Term Investments
Other Short-Term Assets $440.0K $404.4K $913.0K
YoY Change -61.82% -45.62%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $2.729M $4.031M $3.302M
YoY Change 72.25% 13.31% 2.51%
LONG-TERM ASSETS
Property, Plant & Equipment $8.347M $7.735M $8.201M
YoY Change 7.48% 19.55% 174.43%
Goodwill $0.00
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $173.7K $342.7K $139.6K
YoY Change 32.15%
Total Long-Term Assets $9.143M $8.720M $9.194M
YoY Change 15.77% 34.78% 134.46%
TOTAL ASSETS
Total Short-Term Assets $2.729M $4.031M $3.302M
Total Long-Term Assets $9.143M $8.720M $9.194M
Total Assets $11.87M $12.75M $12.50M
YoY Change 25.21% 27.16% 74.95%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $402.0K $670.1K $1.355M
YoY Change -65.24% -23.8% 2170.32%
Accrued Expenses $1.092M $807.6K $361.2K
YoY Change 7.28% 22.09% 749.99%
Deferred Revenue
YoY Change
Short-Term Debt $30.00K $33.85K $33.85K
YoY Change -11.37% 0.0%
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $2.602M $1.949M $1.936M
YoY Change 6.09% 7.34% 538.32%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $630.0K $648.2K $742.4K
YoY Change -11.37% -19.26%
Total Long-Term Liabilities $630.0K $648.2K $742.4K
YoY Change -11.37% -19.26%
TOTAL LIABILITIES
Total Short-Term Liabilities $2.602M $1.949M $1.936M
Total Long-Term Liabilities $630.0K $648.2K $742.4K
Total Liabilities $3.232M $2.597M $2.679M
YoY Change 2.18% -0.82% 133.96%
SHAREHOLDERS EQUITY
Retained Earnings -$19.68M -$15.45M -$7.553M
YoY Change 214.89% 189.62%
Common Stock $383.5K $373.9K $359.1K
YoY Change 27.37% 73.86%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $8.639M $10.15M $9.817M
YoY Change
Total Liabilities & Shareholders Equity $11.87M $12.75M $12.50M
YoY Change 25.21% 27.16% 74.95%

Cashflow Statement

Concept 2023 Q3 2023 Q2 2022 Q4
OPERATING ACTIVITIES
Net Income -$4.222M -$4.286M -$1.304M
YoY Change 115.85% 154.42%
Depreciation, Depletion And Amortization $802.00 $167.00
YoY Change
Cash From Operating Activities -$660.0K -$1.257M -$862.0K
YoY Change -4.94% -9.15%
INVESTING ACTIVITIES
Capital Expenditures $680.0K $146.6K $902.5K
YoY Change -63.0% -91.54%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities -$680.0K -$146.6K -$902.5K
YoY Change -63.0% -91.54%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 0.000 0.000 3.790M
YoY Change -100.0%
NET CHANGE
Cash From Operating Activities -660.0K -1.257M -862.0K
Cash From Investing Activities -680.0K -146.6K -902.5K
Cash From Financing Activities 0.000 0.000 3.790M
Net Change In Cash -1.340M -1.403M 2.026M
YoY Change -47.08% 428.41%
FREE CASH FLOW
Cash From Operating Activities -$660.0K -$1.257M -$862.0K
Capital Expenditures $680.0K $146.6K $902.5K
Free Cash Flow -$1.340M -$1.403M -$1.765M
YoY Change -47.08% -54.96%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2023Q2 us-gaap Assets Current
AssetsCurrent
4030530 usd
CY2023Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
7735166 usd
CY2023Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
642422 usd
CY2023Q2 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
342680 usd
CY2023Q2 us-gaap Assets
Assets
12750798 usd
CY2023Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
670058 usd
CY2023Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
807637 usd
CY2023Q2 us-gaap Notes Payable Current
NotesPayableCurrent
33854 usd
CY2023Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
46565 usd
CY2023Q2 us-gaap Liabilities Current
LiabilitiesCurrent
1948914 usd
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
1936361 usd
CY2023Q2 us-gaap Liabilities
Liabilities
2597099 usd
CY2022Q4 us-gaap Liabilities
Liabilities
2678804 usd
CY2023Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
37385684 shares
CY2023Q2 us-gaap Common Stock Value
CommonStockValue
373857 usd
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
359071 usd
CY2023Q2 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
26455828 usd
CY2022Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
16756426 usd
CY2023Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-15454490 usd
CY2023Q2 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-1211552 usd
CY2022Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
255030 usd
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
10153699 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
9817461 usd
CY2023Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
12750798 usd
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
12496265 usd
CY2023Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
252880 usd
CY2022Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
153389 usd
CY2023Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
404365 usd
CY2023Q2 aspi Fair Value Of Shares Issuable
FairValueOfSharesIssuable
390800 usd
CY2022Q4 aspi Fair Value Of Shares Issuable
FairValueOfSharesIssuable
140455 usd
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
35907127 shares
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-7553066 usd
dei Entity Central Index Key
EntityCentralIndexKey
0001921865
dei Amendment Flag
AmendmentFlag
false
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
500000000 shares
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
35907127 shares
CY2022Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2022Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2023Q2 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2022Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2023Q2 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2022Q2 us-gaap Depreciation
Depreciation
0 usd
CY2023Q2 us-gaap Depreciation
Depreciation
167 usd
CY2022Q4 us-gaap Other Commitment
OtherCommitment
7233000 usd
us-gaap Operating Lease Expense
OperatingLeaseExpense
36530 usd
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
0 shares
CY2022Q2 aspi Warrants To Purchase Common Stock
WarrantsToPurchaseCommonStock
0 shares
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2023-06-30
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-41555
dei Entity Registrant Name
EntityRegistrantName
ASP Isotopes Inc.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
87-2618235
us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
1454 usd
dei Entity Address Address Line1
EntityAddressAddressLine1
1101 Pennsylvania Avenue NW
dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 300
dei Entity Address City Or Town
EntityAddressCityOrTown
Washington
dei Entity Address State Or Province
EntityAddressStateOrProvince
DC
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
20004
dei City Area Code
CityAreaCode
202
dei Local Phone Number
LocalPhoneNumber
756-2245
dei Security12b Title
Security12bTitle
Common Stock, par value $0.01 per share
dei Trading Symbol
TradingSymbol
ASPI
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
dei Entity Ex Transition Period
EntityExTransitionPeriod
false
dei Entity Shell Company
EntityShellCompany
false
CY2023Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
37385684 shares
CY2023Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
3626165 usd
CY2023Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
648185 usd
CY2022Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
742443 usd
CY2023Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2023Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000 shares
CY2023Q2 us-gaap Preferred Stock Value
PreferredStockValue
0 usd
CY2022Q4 us-gaap Preferred Stock Value
PreferredStockValue
0 usd
CY2023Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2023Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
500000000 shares
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
460214 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
446440 usd
CY2023Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
4094664 usd
CY2022Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
674570 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
7612154 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1239772 usd
CY2023Q2 us-gaap Operating Expenses
OperatingExpenses
4347544 usd
CY2022Q2 us-gaap Operating Expenses
OperatingExpenses
827959 usd
us-gaap Operating Expenses
OperatingExpenses
8072368 usd
us-gaap Operating Expenses
OperatingExpenses
1686212 usd
CY2023Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-4347544 usd
CY2022Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-827959 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-8072368 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-1686212 usd
CY2023Q2 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
0 usd
CY2022Q2 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
0 usd
us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-935 usd
us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
0 usd
CY2023Q2 aspi Change In Fair Value Of Share Liability
ChangeInFairValueOfShareLiability
60100 usd
CY2022Q2 aspi Change In Fair Value Of Share Liability
ChangeInFairValueOfShareLiability
0 usd
aspi Change In Fair Value Of Share Liability
ChangeInFairValueOfShareLiability
170385 usd
aspi Change In Fair Value Of Share Liability
ChangeInFairValueOfShareLiability
0 usd
CY2023Q2 us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
1098 usd
CY2022Q2 us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
789 usd
us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
1494 usd
CY2023Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
61198 usd
CY2022Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
789 usd
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
170944 usd
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
1454 usd
CY2023Q2 us-gaap Other Comprehensive Income Loss Before Tax
OtherComprehensiveIncomeLossBeforeTax
-4286346 usd
CY2022Q2 us-gaap Other Comprehensive Income Loss Before Tax
OtherComprehensiveIncomeLossBeforeTax
-827170 usd
us-gaap Other Comprehensive Income Loss Before Tax
OtherComprehensiveIncomeLossBeforeTax
-7901424 usd
us-gaap Other Comprehensive Income Loss Before Tax
OtherComprehensiveIncomeLossBeforeTax
-1684758 usd
CY2023Q2 aspi Net Loss Per Share Basic And Diluted
NetLossPerShareBasicAndDiluted
-0.14
CY2022Q2 aspi Net Loss Per Share Basic And Diluted
NetLossPerShareBasicAndDiluted
-0.03
aspi Net Loss Per Share Basic And Diluted
NetLossPerShareBasicAndDiluted
-0.27
aspi Net Loss Per Share Basic And Diluted
NetLossPerShareBasicAndDiluted
-0.07
CY2022Q2 aspi Weighted Average Shares Of Common Stock Outstanding Basic And Diluted
WeightedAverageSharesOfCommonStockOutstandingBasicAndDiluted
27109754 shares
aspi Weighted Average Shares Of Common Stock Outstanding Basic And Diluted
WeightedAverageSharesOfCommonStockOutstandingBasicAndDiluted
29535060 shares
aspi Weighted Average Shares Of Common Stock Outstanding Basic And Diluted
WeightedAverageSharesOfCommonStockOutstandingBasicAndDiluted
25798098 shares
CY2023Q2 us-gaap Profit Loss
ProfitLoss
-4286346 usd
CY2022Q2 us-gaap Profit Loss
ProfitLoss
-827170 usd
us-gaap Profit Loss
ProfitLoss
-7901424 usd
us-gaap Profit Loss
ProfitLoss
-1684758 usd
CY2023Q2 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax
-472673 usd
CY2022Q2 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax
354528 usd
us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax
-1476526 usd
us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax
125271 usd
CY2023Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-4759019 usd
CY2022Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-472642 usd
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-9377950 usd
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-1559487 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
9817461 usd
CY2023Q1 aspi Issuance Of Common Stock And Warrants Net Of Issuance Costs Amount
IssuanceOfCommonStockAndWarrantsNetOfIssuanceCostsAmount
4493610 usd
CY2023Q1 aspi Cancellation Of Common Stock Received In Exchange For Issuance Of Preferred Stock In Subsidiary Amount
CancellationOfCommonStockReceivedInExchangeForIssuanceOfPreferredStockInSubsidiaryAmount
0 usd
CY2023Q1 aspi Issuance Of Common Stock In Lieu Of Commissions Amount
IssuanceOfCommonStockInLieuOfCommissionsAmount
75570 usd
CY2023Q1 aspi Issuance Of Restricted Common Stock Amount
IssuanceOfRestrictedCommonStockAmount
0 usd
CY2023Q1 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
2144099 usd
CY2023Q1 us-gaap Other Comprehensive Income Loss Foreign Currency Translation Adjustment Tax
OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax
-1003853 usd
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-3615078 usd
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
11911809 usd
CY2023Q2 aspi Settlement Of Liabilities With Related Party
SettlementOfLiabilitiesWithRelatedParty
626223 usd
CY2023Q2 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
2374686 usd
CY2023Q2 us-gaap Other Comprehensive Income Loss Foreign Currency Translation Adjustment Tax
OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax
-472673 usd
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-4286346 usd
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
10153699 usd
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
5997664 usd
CY2022Q1 aspi Issuance Of Common Stock And Warrants Net Of Issuance Cost Amount
IssuanceOfCommonStockAndWarrantsNetOfIssuanceCostAmount
2090186 usd
CY2022Q1 aspi Issuance Of Common Stock Upon Exercise Of Warrants Amount
IssuanceOfCommonStockUponExerciseOfWarrantsAmount
0 usd
CY2022Q1 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
20803 usd
CY2022Q1 us-gaap Other Comprehensive Income Loss Foreign Currency Translation Adjustment Tax
OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax
-229257 usd
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-857588 usd
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
7021808 usd
CY2022Q2 aspi Issuance Of Common Stock Net Of Issuance Costs Of95723 Amount
IssuanceOfCommonStockNetOfIssuanceCostsOf95723Amount
648626 usd
CY2022Q2 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
210745 usd
CY2022Q2 us-gaap Other Comprehensive Income Loss Foreign Currency Translation Adjustment Tax
OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax
354528 usd
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-827170 usd
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
7408537 usd
us-gaap Profit Loss
ProfitLoss
-7901424 usd
us-gaap Profit Loss
ProfitLoss
-1684758 usd
us-gaap Depreciation
Depreciation
167 usd
us-gaap Depreciation
Depreciation
0 usd
us-gaap Share Based Compensation
ShareBasedCompensation
4518785 usd
us-gaap Share Based Compensation
ShareBasedCompensation
231548 usd
aspi Fair Value Of Common Stock To Consultants
FairValueOfCommonStockToConsultants
496300 usd
aspi Fair Value Of Common Stock To Consultants
FairValueOfCommonStockToConsultants
0 usd
us-gaap Liabilities Fair Value Adjustment
LiabilitiesFairValueAdjustment
-170385 usd
us-gaap Liabilities Fair Value Adjustment
LiabilitiesFairValueAdjustment
0 usd
us-gaap Finance Lease Right Of Use Asset Amortization
FinanceLeaseRightOfUseAssetAmortization
32553 usd
us-gaap Finance Lease Right Of Use Asset Amortization
FinanceLeaseRightOfUseAssetAmortization
37476 usd
us-gaap Increase Decrease In Deferred Liabilities
IncreaseDecreaseInDeferredLiabilities
0 usd
us-gaap Increase Decrease In Deferred Liabilities
IncreaseDecreaseInDeferredLiabilities
-154200 usd
us-gaap Increase Decrease In Prepaid Expenses Other
IncreaseDecreaseInPrepaidExpensesOther
294971 usd
us-gaap Increase Decrease In Prepaid Expenses Other
IncreaseDecreaseInPrepaidExpensesOther
-321778 usd
us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
-48747 usd
us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
0 usd
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-351830 usd
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-35716 usd
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
446564 usd
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
576601 usd
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-18844 usd
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-32722 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-2701890 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-1383549 usd
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
508607 usd
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
1732595 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-508607 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-1732595 usd
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
5000000 usd
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
3119560 usd
us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
506390 usd
us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
255965 usd
us-gaap Repayments Of Notes Payable
RepaymentsOfNotesPayable
0 usd
us-gaap Repayments Of Notes Payable
RepaymentsOfNotesPayable
13046 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
4493610 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
2850549 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
1283113 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-265595 usd
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
-46088 usd
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
125285 usd
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
2389140 usd
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
2953721 usd
CY2023Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
3626165 usd
CY2022Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
2813411 usd
aspi Settlement Of Liabilities With Related Party
SettlementOfLiabilitiesWithRelatedParty
626223 usd
aspi Settlement Of Liabilities With Related Party
SettlementOfLiabilitiesWithRelatedParty
0 usd
us-gaap Stock Issued1
StockIssued1
0 usd
us-gaap Stock Issued1
StockIssued1
124782 usd
aspi Unpaid Financing Fees
UnpaidFinancingFees
0 usd
aspi Unpaid Financing Fees
UnpaidFinancingFees
0 usd
us-gaap Noncash Or Part Noncash Acquisition Payables Assumed1
NoncashOrPartNoncashAcquisitionPayablesAssumed1
318900 usd
us-gaap Noncash Or Part Noncash Acquisition Payables Assumed1
NoncashOrPartNoncashAcquisitionPayablesAssumed1
855404 usd
aspi Settlement Of Share Liability
SettlementOfShareLiability
75570 usd
aspi Settlement Of Share Liability
SettlementOfShareLiability
0 usd
us-gaap Profit Loss
ProfitLoss
-7901424 usd
us-gaap Profit Loss
ProfitLoss
-1684758 usd
CY2023Q2 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
3626165 usd
us-gaap Use Of Estimates
UseOfEstimates
<p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 0.5in; text-align:justify;">The Company’s condensed consolidated financial statements are prepared in accordance with accounting principles generally accepted in the United States (“GAAP”). The preparation of the Company’s condensed consolidated financial statements requires management to make estimates and assumptions that impact the reported amounts of assets, liabilities and expenses and disclosure in the Company’s condensed consolidated financial statements and accompanying notes. The most significant estimates in the Company’s consolidated financial statements relate to the valuation of equity instruments and estimating our accrued research and development expenses. Although these estimates are based on the Company’s knowledge of current events and actions it may undertake in the future, actual results may materially differ from these estimates and assumptions.</p>
us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:justify;">Cash balances are maintained at U.S. financial institutions and may exceed the Federal Deposit Insurance Corporation (“FDIC”) insurance limit of $250,000 per depositor, per insured bank for each account ownership category. Although the Company currently believes that the financial institutions with whom it does business, will be able to fulfill their commitments to the Company, there is no assurance that those institutions will be able to continue to do so. The Company has not experienced any credit losses associated with its balances in such accounts for the three and six months ended June 30, 2023 and 2022.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 33.75pt; text-align:justify;">Our foreign subsidiaries held cash of approximately $106,000 and $38,000 as of June 30, 2023 and December 31, 2022, respectively, which is included in cash on the consolidated balance sheets.  Our strategic plan does not require the repatriation of foreign cash in order to fund our operations in the U.S., and it is our current intention to indefinitely reinvest our foreign cash outside of the U.S.  If we were to repatriate foreign cash to the U.S., we would be required to accrue and pay U.S. taxes in accordance with applicable U.S. tax rules and regulations as a result of the repatriation.</p>
CY2023Q2 aspi Federal Deposit Insurance
FederalDepositInsurance
250000 usd
CY2023Q2 us-gaap Common Stock Held By Subsidiary
CommonStockHeldBySubsidiary
106000 usd
CY2022Q4 us-gaap Common Stock Held By Subsidiary
CommonStockHeldBySubsidiary
38000 usd
us-gaap Operating Lease Payments
OperatingLeasePayments
45520 usd
us-gaap Operating Lease Payments
OperatingLeasePayments
50757 usd
CY2023Q2 us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
0 usd
CY2023Q2 us-gaap Fair Value Net Asset Liability
FairValueNetAssetLiability
390800 usd
CY2021Q4 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value
FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
116200 usd
CY2022 aspi Addition On Issuance Of Common Stock
AdditionOnIssuanceOfCommonStock
174782 usd
CY2022 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-150527 usd
CY2022Q4 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value
FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
140455 usd
aspi Hgu
hgu
-75570 usd
aspi Addition On Issuance Of Common Stock
AdditionOnIssuanceOfCommonStock
496300 usd
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-170385 usd
CY2023Q2 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value
FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
390800 usd
CY2022Q2 us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
0 usd
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
0 usd
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
0 usd
CY2023Q2 aspi Remaining Lease Term Years
RemainingLeaseTermYears
P7Y6M
CY2022Q2 aspi Remaining Lease Term Years
RemainingLeaseTermYears
P8Y6M
aspi Remaining Lease Term Years
RemainingLeaseTermYears
P0Y9M
aspi Remaining Lease Term Years
RemainingLeaseTermYears
P8Y9M
CY2023Q2 us-gaap Malpractice Loss Contingency Discount Rate
MalpracticeLossContingencyDiscountRate
0.075 pure
CY2022Q2 us-gaap Malpractice Loss Contingency Discount Rate
MalpracticeLossContingencyDiscountRate
0.075 pure
CY2023Q2 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
7735333 usd
CY2022Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
8200595 usd
CY2023Q2 us-gaap Property Plant And Equipment Other Accumulated Depreciation
PropertyPlantAndEquipmentOtherAccumulatedDepreciation
167 usd
CY2022Q4 us-gaap Property Plant And Equipment Other Accumulated Depreciation
PropertyPlantAndEquipmentOtherAccumulatedDepreciation
0 usd
CY2023Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
7735166 usd
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
8200595 usd
us-gaap Depreciation
Depreciation
167 usd
CY2023Q2 us-gaap Notes Payable Current
NotesPayableCurrent
33854 usd
us-gaap Loss On Contracts
LossOnContracts
6800000 usd
CY2023Q1 us-gaap Other Commitment
OtherCommitment
7233000 usd
us-gaap Deconsolidation Gain Or Loss Amount
DeconsolidationGainOrLossAmount
6050000 usd
CY2023Q2 us-gaap Loss Contingency Receivable Proceeds
LossContingencyReceivableProceeds
626223 usd
CY2021Q4 us-gaap Subordinated Borrowing Interest Rate
SubordinatedBorrowingInterestRate
0.075 pure
CY2021Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
952521 usd
CY2021Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
952521 usd
CY2023Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
642422 usd
CY2023Q2 aspi Operating Lease Lease Liability Current
OperatingLeaseLeaseLiabilityCurrent
46565 usd
CY2023Q2 aspi Operating Lease Lease Liability Noncurrent
OperatingLeaseLeaseLiabilityNoncurrent
648185 usd
CY2023Q2 us-gaap Operating Lease Cost
OperatingLeaseCost
28069 usd
CY2022Q2 us-gaap Operating Lease Cost
OperatingLeaseCost
34739 usd
us-gaap Operating Lease Cost
OperatingLeaseCost
59229 usd
us-gaap Operating Lease Cost
OperatingLeaseCost
70997 usd
CY2023Q2 us-gaap Operating Lease Payments
OperatingLeasePayments
21572 usd
CY2022Q2 us-gaap Operating Lease Payments
OperatingLeasePayments
24836 usd
us-gaap Malpractice Loss Contingency Discount Rate
MalpracticeLossContingencyDiscountRate
0.075 pure
us-gaap Malpractice Loss Contingency Discount Rate
MalpracticeLossContingencyDiscountRate
0.075 pure
CY2023Q2 us-gaap Operating Leases Future Minimum Payments Due Current
OperatingLeasesFutureMinimumPaymentsDueCurrent
48546 usd
CY2023Q2 us-gaap Operating Leases Future Minimum Payments Due In Two Years
OperatingLeasesFutureMinimumPaymentsDueInTwoYears
100733 usd
CY2023Q2 us-gaap Operating Leases Future Minimum Payments Due In Three Years
OperatingLeasesFutureMinimumPaymentsDueInThreeYears
108288 usd
CY2023Q2 us-gaap Operating Leases Future Minimum Payments Due In Four Years
OperatingLeasesFutureMinimumPaymentsDueInFourYears
116409 usd
CY2023Q2 us-gaap Operating Leases Future Minimum Payments Due In Five Years
OperatingLeasesFutureMinimumPaymentsDueInFiveYears
125140 usd
CY2023Q2 us-gaap Operating Leases Future Minimum Payments Due Thereafter
OperatingLeasesFutureMinimumPaymentsDueThereafter
434602 usd
CY2023Q2 us-gaap Operating Leases Future Minimum Payments Due
OperatingLeasesFutureMinimumPaymentsDue
933718 usd
CY2023Q2 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
238968 usd
CY2023Q2 us-gaap Operating Lease Liability
OperatingLeaseLiability
694750 usd
CY2023Q2 aspi Lease Liability Current
LeaseLiabilityCurrent
46565 usd
CY2023Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
648185 usd
CY2023Q2 us-gaap Operating Lease Expense
OperatingLeaseExpense
36530 usd
CY2023Q2 aspi Short Term Operating Lease Future Lease Payments
ShortTermOperatingLeaseFutureLeasePayments
108721 usd
CY2022Q1 us-gaap Other Research And Development Expense
OtherResearchAndDevelopmentExpense
100000 usd
CY2022Q1 aspi Royalty Percentage On Sale Of Products
RoyaltyPercentageOnSaleOfProducts
0.10 pure
CY2022Q4 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
400000 usd
CY2022Q3 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
6000000 usd
CY2023Q2 us-gaap Gain Loss Related To Litigation Settlement
GainLossRelatedToLitigationSettlement
626223 usd
CY2022Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000 shares
aspi Exchange Of Common Shares Into Convertible Preferred Stock
ExchangeOfCommonSharesIntoConvertiblePreferredStock
3000000 shares
CY2023Q2 us-gaap Preferred Stock Convertible Shares Issuable
PreferredStockConvertibleSharesIssuable
2500 shares
CY2023Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
500000000 shares
CY2023Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
37385684 shares
CY2022 us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
1559780 shares
CY2022 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
3119560 usd
CY2022 us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
255965 usd
CY2022Q4 aspi Fair Value Of Shares Issue
FairValueOfSharesIssue
240982 usd
CY2022 us-gaap Stock Issued During Period Shares Other
StockIssuedDuringPeriodSharesOther
120491 shares
CY2022Q4 us-gaap Stock Issued During Period Shares Dividend Reinvestment Plan
StockIssuedDuringPeriodSharesDividendReinvestmentPlan
1250000 shares
CY2022Q4 us-gaap Shares Issued Price Per Share
SharesIssuedPricePerShare
4.00
CY2022Q4 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
3800000 usd
us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
172500 shares
CY2023Q2 aspi Fair Value Of Share Issuable
FairValueOfShareIssuable
56800 shares
CY2023Q1 aspi Fair Value Of Share Issuable
FairValueOfShareIssuable
85400 shares
CY2023Q1 us-gaap Stock Issued During Period Shares Restricted Stock Award Forfeited
StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited
3000000 shares
aspi Cash Director Fees
CashDirectorFees
45000 usd
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Shares Purchased For Award
ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward
3164557 shares
CY2023Q1 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
1.75
CY2023Q1 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
5000000.0 usd
CY2023Q1 us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
506390 usd
CY2023Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
1.66
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
0.603 pure
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
0.0344 pure
aspi Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm
P5Y6M
aspi Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumption Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionExpectedDividendRate
0 pure
CY2023Q2 us-gaap Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Number Of Outstanding Options
ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
6000000 shares
CY2022Q4 us-gaap Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Number Of Outstanding Options
ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
5000000 shares
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
2901000 shares
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
1.91
aspi Weighted Average Remaining Contractual Term In Years Beginning
WeightedAverageRemainingContractualTermInYearsBeginning
P9Y4M24D
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
199500 usd
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
0
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
50000 usd
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
0.25
CY2023Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
2851000 shares
CY2023Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
1.91
aspi Weighted Average Remaining Contractual Term In Years Ending
WeightedAverageRemainingContractualTermInYearsEnding
P8Y10M24D
CY2023Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
47700 usd
CY2023Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
1285025 shares
CY2023Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
1.89
aspi Weighted Average Remaining Contractual Term In Years Exercisable
WeightedAverageRemainingContractualTermInYearsExercisable
P8Y9M18D
CY2023Q2 aspi Aggregate Intrinsic Value Exercisable
AggregateIntrinsicValueExercisable
26500 usd
CY2023Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
2851000 shares
CY2023Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
1.91
aspi Weighted Average Remaining Contractual Term In Years Vested Or Expected To Vest
WeightedAverageRemainingContractualTermInYearsVestedOrExpectedToVest
P8Y10M24D
CY2023Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
47700 usd
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
2116000 shares
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
2.00
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
1.17
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
7000000 shares
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
1.75
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
1256750 shares
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
1.80
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
1389188 shares
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
1.72
CY2023Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
6867562 shares
CY2023Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2374686 usd
CY2022Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
210745 usd
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
4518785 usd
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
231548 usd
CY2023Q2 us-gaap Profit Loss
ProfitLoss
-4286346 usd
CY2022Q2 us-gaap Profit Loss
ProfitLoss
-827170 usd
us-gaap Profit Loss
ProfitLoss
-7901424 usd
us-gaap Profit Loss
ProfitLoss
-1684758 usd
CY2023Q2 us-gaap Weighted Average Number Of Shares Issued Basic
WeightedAverageNumberOfSharesIssuedBasic
29796065 shares
CY2022Q2 us-gaap Weighted Average Number Of Shares Issued Basic
WeightedAverageNumberOfSharesIssuedBasic
27109754 shares
us-gaap Weighted Average Number Of Shares Issued Basic
WeightedAverageNumberOfSharesIssuedBasic
29535060 shares
us-gaap Weighted Average Number Of Shares Issued Basic
WeightedAverageNumberOfSharesIssuedBasic
25798098 shares
CY2023Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.14
CY2022Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.03
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.27
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.07
CY2023Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
2851000 shares
CY2022Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
2266000 shares
CY2023Q2 aspi Warrants To Purchase Common Stock
WarrantsToPurchaseCommonStock
3386076 shares
CY2023Q2 aspi Restricted Stock
RestrictedStock
6867562 shares
CY2022Q2 aspi Restricted Stock
RestrictedStock
2100000 shares
CY2023Q2 aspi Shares Of Common Stock Equivalents
SharesOfCommonStockEquivalents
13104638 shares
CY2022Q2 aspi Shares Of Common Stock Equivalents
SharesOfCommonStockEquivalents
4366000 shares

Files In Submission

Name View Source Status
aspi-20230630_pre.xml Edgar Link unprocessable
aspi-20230630_lab.xml Edgar Link unprocessable
aspi-20230630_def.xml Edgar Link unprocessable
aspi-20230630_cal.xml Edgar Link unprocessable
R2.htm Edgar Link pending
0001477932-23-006112-index-headers.html Edgar Link pending
0001477932-23-006112-index.html Edgar Link pending
0001477932-23-006112.txt Edgar Link pending
0001477932-23-006112-xbrl.zip Edgar Link pending
aspi-20230630.xsd Edgar Link pending
aspi_10q.htm Edgar Link pending
aspi_ex311.htm Edgar Link pending
aspi_ex312.htm Edgar Link pending
aspi_ex321.htm Edgar Link pending
aspi_ex322.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
aspi_10q_htm.xml Edgar Link completed
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending